XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 29.81

-4.3%

Dec 2 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bluegreen who wrote (16354)	10/19/2003 12:50:24 PM
From: Robert K.	of 17367

Cytotoxic vs cytostatic......The plot thickens..... >http://www.bloodjournal.org/cgi/content/full/96/1/176 "A novel biological activity for BPI has been reported in this study. BPI has joined the list of antiangiogenic agents that include PF4, angiostatin,22 and endostatin.23 More and more angiogenesis inhibitors are continually being discovered, and only a few will ever be used in therapeutic applications. BPI, aside from providing a potential treatment against sepsis, might also be used in the treatment of cancer and/or other angiogenesis-related pathological disorders. In its capacity as an antiangiogenic agent, BPI works specifically on and is cytotoxic to ECs, whereas both PF4 and endostatin, for example, are cytostatic, arresting ECs in the cell cycle

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next